The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...
A research study co-authored by Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders will be ...
Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk ...
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...
In August 2024, the U.S. Food and Drug Administration (FDA) granted bexmarilimab fast track designation, acknowledging its potential to address unmet medical needs in MDS treatment. The interim ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...
GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback